- Home
- CANF vs AIMAU Comparison
CANF vs AIMAU Comparison
Compare CANF & AIMAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- AIMAU
- Stock Information
- Founded
- CANF 1994
- AIMAU 2021
- Country
- CANF Israel
- AIMAU United States
- Employees
- CANF N/A
- AIMAU N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- AIMAU
- Sector
- CANF Health Care
- AIMAU
- Exchange
- CANF Nasdaq
- AIMAU NYSE
- Market Cap
- CANF 7.9M
- AIMAU N/A
- IPO Year
- CANF N/A
- AIMAU 2022
- Fundamental
- Price
- CANF $1.12
- AIMAU $19.26
- Analyst Decision
- CANF Strong Buy
- AIMAU
- Analyst Count
- CANF 2
- AIMAU 0
- Target Price
- CANF $14.00
- AIMAU N/A
- AVG Volume (30 Days)
- CANF 444.9K
- AIMAU 257.0
- Earning Date
- CANF 05-20-2025
- AIMAU 01-01-0001
- Dividend Yield
- CANF N/A
- AIMAU N/A
- EPS Growth
- CANF N/A
- AIMAU N/A
- EPS
- CANF N/A
- AIMAU 0.20
- Revenue
- CANF $674,000.00
- AIMAU N/A
- Revenue This Year
- CANF $461.72
- AIMAU N/A
- Revenue Next Year
- CANF N/A
- AIMAU N/A
- P/E Ratio
- CANF N/A
- AIMAU $94.27
- Revenue Growth
- CANF N/A
- AIMAU N/A
- 52 Week Low
- CANF $1.02
- AIMAU $11.22
- 52 Week High
- CANF $4.69
- AIMAU $19.26
- Technical
- Relative Strength Index (RSI)
- CANF 40.25
- AIMAU 72.74
- Support Level
- CANF $1.02
- AIMAU $13.05
- Resistance Level
- CANF $1.20
- AIMAU $17.00
- Average True Range (ATR)
- CANF 0.06
- AIMAU 0.17
- MACD
- CANF 0.01
- AIMAU 0.12
- Stochastic Oscillator
- CANF 41.30
- AIMAU 100.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About AIMAU AIMFINITY INVESTMENT CORP
Aimfinity Investment Corp I is a blank check company. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar Business Combination with one or more businesses.